A curable pseudo-dementia related to an atypical presentation of giant cell arteritis

Clément Lahaye1, Manuel Sanchez2, Audrey Rouet3

  • 1Unité mobile de Gériatrie, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France.

Age and Ageing
|March 10, 2020
PubMed

Insights

Giant cell arteritis (GCA) can cause rapid cognitive decline and ataxia. Prompt diagnosis and treatment with corticosteroids and immunosuppressants led to symptom improvement in this rare case.

Area of Science:

  • Neurology
  • Rheumatology
  • Vascular Medicine

Background:

  • Giant cell arteritis (GCA) is a systemic vasculitis typically affecting large and medium arteries.
  • Cranial GCA commonly presents with headache and visual disturbances, but neurological manifestations can be diverse.
  • Atypical presentations, including significant cognitive decline, are less common but recognized complications.

Observation:

  • A 70-year-old patient presented with rapid cognitive decline, functional impairment, weight loss, and cerebellar ataxia.
  • 18FDG-PET imaging revealed metabolically active vasculitis in the brachiocephalic trunk.
  • Temporal artery biopsy confirmed pan-arteritis, leading to a diagnosis of GCA with vascular involvement.

Findings:

  • The patient experienced progressive cognitive improvement following treatment with corticosteroids and immunosuppressive therapy.
  • This case highlights the potential for GCA to manifest with severe neurological symptoms, including cognitive impairment and ataxia.
  • Published reports suggest a range of cognitive symptoms, such as memory impairment and delirium, may be linked to GCA.

Implications:

  • GCA should be considered in the differential diagnosis of unexplained cognitive impairment, especially when accompanied by systemic inflammation and weight loss.
  • Early recognition and treatment of GCA can lead to reversible neurological deficits and improved patient outcomes.
  • This case underscores the importance of advanced imaging (18FDG-PET) and biopsy in diagnosing GCA with atypical vascular and neurological involvement.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
268
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
697
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
344
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
871